ReNu, as previously discussed, is cryopreserved human amniotic membrane (HAM) and human amniotic fluid derived cells, which include “stem cells” (HAFCs). This tissue is obtained from healthy volunteer donors. Specifically, this is NOT fetal tissue. It is the fluid and the placenta that would normally be discarded at childbirth. Fortunately, with preservation and separation of the layers of the placenta, the amnion layer and cells can be preserved to make use of their unique properties.
Dr. Jack Farr's Blog
I am beginning a study of the KineSpring® System as the chief primary investigator. The KineSpring System is intended to treat symptoms of pain and loss of function caused by medial compartment knee osteoarthritis.
Right now, doctors at 5 other sites in the United State are working with me on this clinical research study, the SOAR Clinical Trial, to evaluate the safety and effectiveness of the KineSpring System for the treatment of knee osteoarthritis.
A new pilot clinical study evaluating a new treatment option for osteoarthritis symptoms is currently available only at OrthoIndy. There is no charge if patients meet inclusion/exclusion criteria. The treatment is a single knee injection. The injection is a suspension of micro-pulverized frozen amniotic membrane and amniotic fluid stem cells.
The goal of the meeting was to introduce basic science avant-garde concepts to current practitioners of cartilage both in the clinical and business world of cartilage. The concepts ranged from whole limb regeneration to stem cells to genetic evaluation of cartilage degeneration risk factors.
When “new” knee anatomy makes headlines not only in an academic journal, but also in Time magazine and is an answer on Jeopardy, it must be a spectacular discovery. The reality is that the ligament, the anterior lateral ligament or ALL, was first observed by a French surgeon, Segund, in 1876.
This is an independent Biography on Jack Farr by Elizabeth Hofheinz, MEd, MPH which appeared in Orthopedics This Week (www.http://ryortho.com/) on May 5th, 2009
"Whether studying replication in fruit flies or working on a design team for a meniscal product, Dr. Jack Farr, an orthopedic surgeon and founder of the OrthoIndy Cartilage Restoration Center of Indiana (Indianapolis, Indiana), likes to excavate all of the important details surrounding a problem. And then he moves forward.
In the recent past, the popular press excitedly reported the promise of stem cells for all tissues of the body. Today, there remains a public perception that stem cells can “grow into anything” from a new pancreas to a new meniscus; however, in reality stem cell research still has much to learn.
The first meeting of world meniscal reconstruction experts in Toronto 2013 demonstrated to all that there is more agreement than disagreement in the global approach to meniscal problems. With 25 experts in attendance, it was obvious this is an important topic across the world-- many of the pioneer transplant surgeons have over 20 years of experience. Meniscal transplantation is neither investigation nor experimental and thousands of patients have had years of pain relief following transplantation.
Unfortunately, the general treatment options for cartilage restoration in the United States have remained somewhat stagnant for more than 15 years. Fortunately, within this static group of specific cartilage treatments, surgeons have expanded the areas of treatment both in the knee and other joints. Initially, the technique was primarily use for femoral lesions.
After the first patellar dislocation, a percentage of patients will experience another dislocation(s). The probability of this occurring is related to certain risks factors that can be identified with x-rays and MRI. The most commonly cited risk factors, which will be discussed below, are: 1) high riding patella, 2) excessive lateral position of the attachment of the patellar tendon attachment to the tibia, 3) “knock-knees”, 4) residual excessive looseness of the medial patellofemoral ligament, 5) poor trochlear groove shape.